Changchun High-Tech's subsidiary, Jinsai Pharmaceutical, has received acceptance for its marketing application for Jintuximabs Injection from China's National Medical Products Administration. This drug is intended for use in combination with paclitaxel for advanced gastric or gastroesophageal junction adenocarcinoma patients who have previously failed first-line systemic treatment. Separately, Sanfu New Material's controlling shareholder proposed a share buyback of 20-30 million yuan for employee incentives. AI
RANK_REASON The primary news is a drug marketing application acceptance, which is a product-related event but not a frontier release from a major AI lab. Other news items are unrelated.
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
